Home Cart Sign in  
Chemical Structure| 118288-08-7 Chemical Structure| 118288-08-7

Structure of Lafutidine
CAS No.: 118288-08-7

Chemical Structure| 118288-08-7

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Lafutidine is an antagonist of histamine H(2)-receptor that inhibits gastric acid secretion.

Synonyms: FRG-8813; (+)-Lafutidine

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Lafutidine

CAS No. :118288-08-7
Formula : C22H29N3O4S
M.W : 431.55
SMILES Code : O=C(NC/C=C\COC1=NC=CC=C1CN2CCCCC2)CS(CC3=CC=CO3)=O
Synonyms :
FRG-8813; (+)-Lafutidine
MDL No. :MFCD21607521

Safety of Lafutidine

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Related Pathways of Lafutidine

GPCR

Isoform Comparison

Biological Activity

Target
  • H2 receptor

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT02703896 Pulmonary Aspiration of Gastri... More >>c Contents Less << Phase 4 Completed - -
NCT02555852 - Completed - Canada, Quebec ... More >> Lady Davis Institute for Medical Research, Jewish General Hospital Montreal, Quebec, Canada, H3T1E2 Less <<
NCT00229424 Gastroesophageal Reflux Phase 3 Completed - Japan ... More >> Tohoku University Hospital 1-1, Seiryo-cho, Aoba-ku, Sendai, Miyagi, Japan, 980-8574 Less <<
NCT01499368 Erosive Esophagitis Phase 3 Completed - -
NCT02759224 Gastric Ulcer Phase 1 Completed - Korea, Republic of ... More >> The Catholic University of Korea, Seoul St.Mary's Hospital Seoul, Korea, Republic of Less <<
NCT02658864 Chronic Gastritis Phase 1 Completed - -
NCT02581696 Peptic Ulcer Phase 1 Completed - Korea, Republic of ... More >> The Catholic University of Korea, Seoul St.Mary's Hospital Seoul, Korea, Republic of Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.32mL

0.46mL

0.23mL

11.59mL

2.32mL

1.16mL

23.17mL

4.63mL

2.32mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

[1]Namikawa T, Munekage E, et al. Feasibility study of supportive care using lafutidine, a histamine H2 receptor antagonist, to prevent gastrointestinal toxicity during chemotherapy for gastric cancer. Anticancer Res. 2014 Dec;34(12):7297-301.

[2]Tanaka M, Banba M, et al. Pharmacological and therapeutic properties of lafutidine (stogar and protecadin), a novel histamine H2 receptor antagonist with gastroprotective activity. Nihon Yakurigaku Zasshi. 2001 Jun;117(6):377-86.

[3]Sano T, Utsumi D, Amagase K, Matsumoto K, Tominaga M, Higuchi K, Takeuchi T, Kato S. Lafutidine, a histamine H2 receptor antagonist with mucosal protective properties, attenuates 5-fluorouracil-induced intestinal mucositis in mice through activation of extrinsic primary afferent neurons. J Physiol Pharmacol. 2017 Feb;68(1):79-90

[4]Tanaka M, Banba M, Joko A, Moriyama Y. [Pharmacological and therapeutic properties of lafutidine (stogar and protecadin), a novel histamine H2 receptor antagonist with gastroprotective activity]. Nihon Yakurigaku Zasshi. 2001 Jun;117(6):377-86. Japanese

[5]Yoneda M, Kurosawa M, Watanobe H, Terano A. Lafutidine increases hepatic blood flow via potentiating the action of central thyrotropin-releasing hormone in rats. J Gastroenterol Hepatol. 2003 Feb;18(2):177-84

[6]Kim EH, Lee YC, Chang YW, Park JJ, Chun HJ, Jung HY, Kim HS, Jeong HY, Seol SY, Han SW, Choi MG, Park SH, Lee OJ, Jung JT, Lee DH, Jung HC, Lee ST, Kim JG, Youn SJ, Kim HY, Lee SW. Efficacy of Lafutidine Versus Famotidine in Patients with Reflux Esophagitis: A Multi-Center, Randomized, Double-Blind, Non-inferiority Phase III Trial. Dig Dis Sci. 2015 Jun;60(6):1724-32

 

Historical Records

Categories